{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:28:04Z","timestamp":1790116084492,"version":"4.0.1"},"reference-count":30,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,11,15]]},"abstract":"<jats:sec id=\"abs1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Emerging data have supported the immunostimulatory role of radiotherapy, which could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but suboptimal effect of ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed a pilot study to explore the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab and chemotherapy in TNBC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Treatment-na\u00efve TNBC patients received two cycles of intravenous adebrelimab (20 mg\/kg, every 3 weeks), and SBRT (24 Gy\/3 f, every other day) started at the second cycle, then followed by six cycles of adebrelimab plus nab-paclitaxel (125 mg\/m\u00b2 on days 1 and 8) and carboplatin (area under the curve 6 mg\/mL per min on day 1) every 3 weeks. The surgery was performed within 3\u20135 weeks after the end of neoadjuvant therapy. Primary endpoint was pathological complete response (pCR, ypT0\/is ypN0). Secondary endpoints included objective response rate (ORR), residual cancer burden (RCB) 0-I, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs3\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>13 patients were enrolled and received at least one dose of therapy. 10 (76.9%) patients completed SBRT and were included in efficacy analysis. 90% (9\/10) of patients achieved pCR, both RCB 0-I and ORR reached 100% with three patients achieved complete remission. Adverse events (AEs) of all-grade and grade 3\u20134 occurred in 92.3% and 53.8%, respectively. One (7.7%) patient had treatment-related serious AEs. No radiation-related dermatitis or death occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs4\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Adding SBRT to adebrelimab and neoadjuvant chemotherapy led to a substantial proportion of pCR with acceptable toxicities, supporting further exploration of this combination in TNBC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs5\">\n                    <jats:title>Funding:<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs6\">\n                    <jats:title>Clinical trial number:<\/jats:title>\n                    <jats:p>\n                      <jats:related-object document-id=\"NCT05132790\" document-id-type=\"clinical-trial-number\" id=\"RO1\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/show\/NCT05132790\">NCT05132790<\/jats:related-object>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.7554\/elife.91737","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T14:15:05Z","timestamp":1701267305000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.91737","source":"Crossref","is-referenced-by-count":25,"title":["Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study"],"prefix":"10.7554","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct05132790","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Guanglei","family":"Chen","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Gu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqi","family":"Xue","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Yu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"id":[{"id":"https:\/\/ror.org\/008w1vb37","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijin","family":"He","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyue","family":"Tang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xing","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiao","family":"Yin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Bian","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-8122","authenticated-orcid":true,"given":"Ye","family":"Han","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Cao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Jiang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Liaoning Center for Drug Evaluation and Inspection","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04ayvvz32","id-type":"ROR","asserted-by":"publisher"}],"name":"Jiangsu Hengrui Pharmaceuticals","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04ayvvz32","id-type":"ROR","asserted-by":"publisher"}],"name":"Jiangsu Hengrui Pharmaceuticals","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Niu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-235X","authenticated-orcid":true,"given":"Caigang","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"id":[{"id":"https:\/\/ror.org\/032d4f246","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Northeastern Clinical Research Alliance of Oncology (NCRAO)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1175","article-title":"A systematic review of neo-adjuvant radiotherapy in the treatment of breast cancer","volume":"15","author":"Ahmed","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1470-2045(15)00222-3","article-title":"Expanding global access to radiotherapy","volume":"16","author":"Atun","year":"2015","journal-title":"The Lancet. Oncology"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ijrobp.2012.10.034","article-title":"Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer","volume":"85","author":"Bondiau","year":"2013","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"bib4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00940-z","article-title":"SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges","volume":"13","author":"Chen","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMc1713349","article-title":"Recent Developments in Radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ctrv.2016.12.010","article-title":"Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development","volume":"53","author":"Costa","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"key":"bib8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.002","article-title":"Corrigendum to \u201cFirst-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis\u201d: Annals of Oncology 2021; 32: 983-993","volume":"32","author":"Emens","year":"2021","journal-title":"Annals of Oncology"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"bib10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112692","article-title":"Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model","volume":"14","author":"Han","year":"2022","journal-title":"Cancers"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.radonc.2020.11.007","article-title":"SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer","volume":"155","author":"Holyoake","year":"2021","journal-title":"Radiotherapy and Oncology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of Immunotherapy in Triple-Negative Breast Cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"bib13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60871-0","article-title":"Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis","volume":"10","author":"Kishi","year":"2020","journal-title":"Scientific Reports"},{"key":"bib14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.901312","article-title":"Feasibility and Short-Term Toxicity of a Consecutively Delivered Five Fraction Stereotactic Body Radiation Therapy Regimen in Early-Stage Breast Cancer Patients Receiving Partial Breast Irradiation","volume":"12","author":"Liu","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"bib16","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-PD10-01","article-title":"Abstract PD10-01: The PEARL trial: Pre-operative pembrolizumab with radiation therapy in early stage triple negative breast cancer","volume":"82","author":"McArthur","year":"2022","journal-title":"Cancer Research"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Annals of Oncology"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10585-022-10167-6","article-title":"Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients","volume":"39","author":"Nicosia","year":"2022","journal-title":"Clinical & Experimental Metastasis"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.radonc.2021.05.025","article-title":"Preoperative stereotactic ablative body radiotherapy with postoperative conventional irradiation of soft tissue sarcomas: Protocol overview with a preliminary safety report","volume":"161","author":"Novikov","year":"2021","journal-title":"Radiotherapy and Oncology"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","article-title":"PD-1 Restrains Radiotherapy-Induced Abscopal Effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunology Research"},{"key":"bib22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1830524","article-title":"Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade","volume":"9","author":"Pilones","year":"2020","journal-title":"Oncoimmunology"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000528640","article-title":"Stereotactic radiotherapy in early-stage breast cancer in neoadjuvant and exclusive settings: a systematic review","volume":"46","author":"Piras","year":"2023","journal-title":"Oncology Research and Treatment"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Annals of Oncology"},{"key":"bib25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2006684","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer. Reply","volume":"382","author":"Schmid","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"bib26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.953810","article-title":"Stereotactic partial breast irradiation in primary breast cancer: A comprehensive review of the current status and future directions","volume":"12","author":"Takanen","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.radonc.2021.09.031","article-title":"Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis","volume":"164","author":"Viani","year":"2021","journal-title":"Radiotherapy and Oncology"},{"key":"bib28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0520-5","article-title":"Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nature Medicine"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"The Lancet. Oncology"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2022.09.222","article-title":"Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial","volume":"18","author":"Yan","year":"2023","journal-title":"Journal of Thoracic Oncology"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/91737\/elife-91737-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/91737\/elife-91737-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/91737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T05:15:46Z","timestamp":1703222146000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/91737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":30,"alternative-id":["10.7554\/eLife.91737"],"URL":"https:\/\/doi.org\/10.7554\/elife.91737","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.14.23294091","asserted-by":"subject"},{"id-type":"doi","id":"10.1101\/2023.08.14.23294091","asserted-by":"subject"},{"id-type":"doi","id":"10.1101\/2023.08.14.23294091","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.7554\/eLife.91737.sa2","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.91737.sa0","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.91737.sa1","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"e91737"}}